A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorThe Christie NHS Foundation Trust
About this trial
To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Have no MRI contra-indications.
Eligible for abdominal SABR in accordance with the NHSE SABR Consortium Guidelines or eligible for central lung SABR in accordance with RTOG Guidelines.
Be able to give informed consent.
Anticipated life-expectancy > 6 months.
Disqualifiers
Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
Unable to tolerate MRI scans.
Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator make it undesirable for the patient to participate in the study.
Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make it undesirable for the patient to participate in the study.
Trial population
Either patient with abdominal cancer or centrally located lung cancer eligible for SABR
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
> 85% success in delivery and completion of radiotherapy to patients recruited on protocol
Time frame
30 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov